22 results on '"Emin Tamer Elkiran"'
Search Results
2. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study
- Author
-
Irfan Cicin, Mehmet Artac, Feyyaz Ozdemir, Metin Ozkan, Mustafa Benekli, Nezih Meydan, Sadettin Kilickap, Alper Sevinc, Abdurrahman Isikdogan, Faysal Dane, Mehmet Aliustaoglu, Berna Oksuzoglu, Mahmut Gumus, Emin Tamer Elkiran, and Ozgur Ozyilkan
- Subjects
Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Turkey ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.medical_treatment ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Progression-free survival ,Metastatic renal cell cancer ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,business.industry ,Middle Aged ,Kidney Neoplasms ,respiratory tract diseases ,Treatment Outcome ,030104 developmental biology ,Cytokine ,030220 oncology & carcinogenesis ,Cytokines ,Female ,Observational study ,business ,Tyrosine kinase - Abstract
Objective Cytokines have been the mainstay of treatment in metastatic renal cell cancer (mRCC) for decades before the introduction of tyrosine kinase inhibitors (TKIs), which dramatically changed the therapeutic landscape in these patients. This observational study was designed to evaluate use of TKIs in the treatment of cytokine-intolerant mRCC patients. Methods A total of 151 cytokine-intolerant mRCC patients who were treated with TKIs (sunitinib, pazopanib and sorafenib) were enrolled in this prospective, non-interventional, multi-center observational study at 16 oncology centers across Turkey. Mean (SD) age was 61.3 (11.1) years and 74.8% were males. Data on duration of TKI treatment was the primary outcome measure. Additionally, overall response rate (ORR), progression free survival (PFS), overall survival (OS) and safety data were recorded. Results Median duration of treatment was 8.2 months at a median follow up of 17.9 months. ORR and disease control rate were 12.5% and 70.8%, respectively. Median PFS and OS were 7.5 months (95%CI: 6.4–10.4) and 27.3 months (95%CI: 17.6–27.3) with no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. The most common adverse events excluding progression-which was the protocol requirement were diarrhea (13.6%), asthenia (13.6%) and hand-foot syndrome (12.6%). Dose modifications were required in 30.5% of the patients and 15% discontinued TKIs because of toxicity. Conclusions Our findings confirm the efficacy and safety profile of TKIs in the first-line treatment of mRCC patients intolerant to cytokine treatment. There was no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. Trial registration: TURCOS ClinicalTrials.gov Identifier: NCT01585974. Registered April 25, 2012.
- Published
- 2020
3. Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)
- Author
-
Alper Sevinc, Erdem Cubukcu, Aziz Karaoglu, Berna Oksuzoglu, Metin Ozkan, Arife Ulas, Gamze Gokoz-Dogu, Emin Tamer Elkiran, Faysal Dane, Murat Koçer, Abdurrahman Isikdogan, Mukremin Uysal, Mehmet Aliustaoglu, Irfan Cicin, Mustafa Benekli, and Ersin Ozaslan
- Subjects
Male ,drug safety ,030204 cardiovascular system & hematology ,Turkey (republic) ,computer assisted tomography ,0302 clinical medicine ,Risk Factors ,Neoplasms ,middle aged ,bemiparin ,low molecular weight heparin ,adult ,clinical trial ,enoxaparin ,Venous Thromboembolism ,Hematology ,General Medicine ,Middle Aged ,Thrombosis ,Doppler ultrasonography ,female ,Tolerability ,priority journal ,risk factor ,thrombus ,030220 oncology & carcinogenesis ,laboratory test ,Female ,VTE ,Aged ,Follow-Up Studies ,Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects ,Humans ,Neoplasms/blood/*drug therapy ,Venous Thromboembolism/blood/etiology/*prevention & control ,prospective study ,medicine.medical_specialty ,Gastrointestinal bleeding ,venous thromboembolism ,gastrointestinal hemorrhage ,malignant neoplasm ,Article ,cancer chemotherapy ,03 medical and health sciences ,remission ,blood ,Internal medicine ,medicine ,follow up ,cancer ,human ,Thrombus ,thrombosis ,tinzaparin ,anticoagulant therapy ,business.industry ,Cancer ,Original Articles ,Tinzaparin ,thromboembolism ,Heparin, Low-Molecular-Weight ,medicine.disease ,major clinical study ,LMWH ,drug efficacy ,multicenter study ,Observational study ,observational study ,business ,Venous thromboembolism ,neoplasm - Abstract
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer who are at low risk of venous thromboembolism (VTE). Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed up for a period of 12 months. Due to the study design, there was no specific treatment protocol for LMWH. Primary end points were efficacy and the time to change in VTE status. Of the included 250 patients, 239 (95.6%), 176 (70.4%), 130 (52.0%), and 91 (36.4%) completed their day 15, month 3, month 6, and month 12 visits, respectively. Number of patients treated with enoxaparin, bemiparin, and tinzaparin were 133, 112, and 5, respectively. Anticoagulant therapy provoked thrombus resolution in 1.2% and 12.7% of patients using enoxaparin and bemiparin, respectively ( P = .004). Thrombus resolution was observed in 81 more patients at month 3 visit. This ratio was 35 (40.2%) of 87 and 46 (54.1%) of 85 patients administered enoxaparin and bemiparin at the third visit, respectively ( P = .038). Thrombus resolution was observed in 21 more patients during month 6 visit. This ratio was 5 (7.7%) of 65 and 15 (23.4%) of 64 patients administered enoxaparin and bemiparin at the fourth visit, respectively ( P = .022). The LMWH was discontinued in only 2 patients due to gastrointestinal bleeding. This pioneering study shows bemiparin is more effective than enoxaparin in thrombosis resolution and has a similar tolerability profile.
- Published
- 2018
4. Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA)
- Author
-
Erdem Cubukcu, Arife Ulas, Emin Tamer Elkiran, Mustafa Benekli, Mehmet Aliustaoglu, Alper Sevinc, Gamze Gokoz Dogu, Abdurrahman Isikdogan, Berna Oksuzoglu, Irfan Cicin, Faysal Dane, Mukremin Uysal, Ersin Ozaslan, Aziz Karaoglu, Murat Koçer, and Metin Ozkan
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Turkish ,Cancer ,medicine.disease ,language.human_language ,Oncology ,Internal medicine ,medicine ,language ,In patient ,Observational study ,business ,Venous thromboembolism - Abstract
e21656 Background: Venous thromboembolism (VTE) is one of the most important causes of death in cancer patients, with VTE risk being 4-7 times higher among these patients compared to normal population. TREBECA is an observational study on cancer outpatients with low risk VTE treated with LMWH. Methods: Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed-up for a period of 12 months. Each center used their own treatment protocol. Primary endpoints were efficacy and the time to a change inVTE status (dissolution of thrombosis). The doses of LMWHs have been calculated according to patients’ body weights based on the dosage scheme and administered subcutaneously once or twice daily. Results: Data for 250 patients who met the study inclusion criteria were examined and analyzed. Of the included patients; 239 patients (95.6%) completed their Day 15 visit, 176 (70.4%) completed their Month 3 visit, 130 (52.0%) completed their Month 6 visit, and 91 (36.4%) completed the entire study. The mean age of the patients was 60.2 ± 13.7, while 53.2% (n = 133) of the patients were women. Colorectal (21.2%), lung (16.8%) and breast (14.8%) cancers were the most common forms of cancer. One hundred thirty-three patients were treated with enoxaparin, 112 patients were treated with bemiparin and 5 patients were treated with tinzaparin. Bemiparin resulted thrombosis resolution in more patients than enoxaparin, during day 15, month 3 and month 6 visits (table 1; p < 0.05). Conclusions: The observation that bemiparin is more effective in resolution of thrombosis was noteworthy. Thrombosis could not be effectively treated within the first 15 days in a significant number of patients, but could effectively be treated in most patients by Month 3. We can conclude that a treatment of at least 3 months is appropriate for cancer patients, even among those who are at low risk for venous thromboembolism. [Table: see text]
- Published
- 2017
5. Oxidative stress and antioxidant parameters in neutropenic patients secondary to chemotherapy
- Author
-
Selçuk İlhan, Akif Dogantekin, Emin Tamer Elkiran, Ali Gürel, and Bilal Ustundag
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Neutropenia ,Filgrastim ,Gastroenterology ,Arylesterase ,chemistry.chemical_compound ,Internal medicine ,Lactate dehydrogenase ,Malondialdehyde ,Neutropenia secondary to chemotherapy ,Medicine ,Chemotherapy ,biology ,business.industry ,Paraoxonase ,General Medicine ,medicine.disease ,PON1 ,chemistry ,Oxidative stress ,biology.protein ,Original Article ,Antioxidant ,business ,medicine.drug - Abstract
Objective: Neutropenia is a serious adverse event that necessitates dosage reduction in patients receiving chemotherapy. In this study, we evaluated the oxidative stress and antioxidant parameters in neutropenic patients after chemotherapy both during the neutropenic period and after successful treatment of neutropenia with filgrastim. Methods: We studied paraoxonase (PON1), arylesterase (ARE), malondialdehyde (MDA), high-density lipoprotein (HDL), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP) in addition to routine biochemical and hematologic parameters. SPSS 12.0 was used for statistical evaluation of data (SPSS, Chicago, IL, USA). Results: In our study, PON1, HDL, and LDH levels during the period of active neutropenia were statistically significantly higher than these levels were after resolution of neutropenia (P
- Published
- 2016
6. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO
- Author
-
Ozan Yazici, Nuriye Ozdemir, Ayse Ocak Duran, Serkan Menekse, Mehmet Ali, Nahit Sendur, Halit Karaca, Gamze Goksel, Erkan Arpaci, Hacıbekiroğlu, İlhan, Irem Bilgetekin, Turgut Kacan, Metin Ozkan, Sercan Aksoy, Asude Aksoy, Suna Cokmert, Uysal, Mehmet, Emin Tamer Elkiran, Irfan Cicin, Suleyman Buyukberber, Nurullah Zengin, Yazici, O, Ozdemir, N, Duran, AO, Menekse, S, Ali, M, Sendur, N, Karaca, H, Goksel, G, Arpaci, E, Hacibekiroglu, I, Bilgetekin, I, Kacan, T, Ozkan, M, Aksoy, S, Aksoy, A, Cokmert, S, Uysal, M, Elkiran, ET, Cicin, I, Buyukberber, S, Zengin, N, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Hacıbekiroğlu, İlhan, Uysal, Mehmet, [Yazici, Ozan -- Aksoy, Sercan -- Zengin, Nurullah] Ankara Numune Training & Res Hosp, Dept Med Oncol, TR-06410 Ankara, Turkey -- [Ozdemir, Nuriye -- Sendur, Nahit] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, TR-06800 Ankara, Turkey -- [Duran, Ayse Ocak -- Karaca, Halit -- Ozkan, Metin] Erciyes Univ, Fac Med, Dept Med Oncol, TR-38030 Kayseri, Talas Melikgazi, Turkey -- [Menekse, Serkan -- Goksel, Gamze] Celal Bayar Univ, Fac Med, Dept Med Oncol, TR-45030 Uncubozkoy, Manisa, Turkey -- [Arpaci, Erkan] Sakarya Univ, Educ & Res Hosp, Dept Med Oncol, TR-54100 Sirinevler, Sakarya, Turkey -- [Hacibekiroglu, Ilhan] Trakya Univ, Fac Med, Dept Med Oncol, TR-22050 Karaagac, Edirne, Turkey -- [Bilgetekin, Irem -- Buyukberber, Suleyman] Gazi Univ, Fac Med, Dept Med Oncol, TR-06560 Emniyet, Ankara, Turkey -- [Kacan, Turgut] Cumhuriyet Univ, Fac Med, Dept Med Oncol, TR-58140 Sivas, Imaret, Turkey -- [Aksoy, Sercan -- Elkiran, Emin Tamer] Inonu Univ, Fac Med, Dept Med Oncol, TR-44000 Malatya, Centre, Turkey -- [Cokmert, Suna] Izmir Kent Hosp, Dept Med Oncol, Izmir, Turkey -- [Uysal, Mukremin] Afyon Kocatepe Univ, Fac Med, Afyon, Turkey, Aksoy, Sercan -- 0000-0003-4984-1049, and aksoy, asude -- 0000-0002-5609-9658
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Gastroenterology ,survival ,Metastatic gastric cancer ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Gastrectomy ,Stomach Neoplasms ,Surgical removal ,Internal medicine ,medicine ,Humans ,In patient ,resection ,advanced gastric cancer ,Peritoneal Neoplasms ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Hazard ratio ,General Medicine ,Advanced gastric cancer ,Middle Aged ,medicine.disease ,Primary tumor ,gastrectomy ,Surgery ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Multivariate Analysis ,030211 gastroenterology & hepatology ,Female ,business - Abstract
WOS: 000368937200011, PubMed ID: 26775722, Aim: To investigate the role of surgical resection of primary tumor on overall survival (OS) in advanced gastric cancer patients at the time of diagnosis. Patients & methods: The survival rates of metastatic gastric cancer patients whose gastric primary tumor was resected at time of diagnosis were compared with metastatic gastric cancer patients whose primary tumor was nonresected. Results: The median progression-free survival and OS in operated and nonoperated group were 10 versus 6, 14 versus 9 months, respectively (p < 0.001). In multivariate analysis, gastric resection of primary tumor, Eastern Cooperative Oncology Group performance status, second-line chemotherapy had a significant effect on OS (hazard ratio [HR]: 0.52 [95% CI: 0.38-0.71], HR: 0.57 [95% CI: 0.42-0.78], HR: 1.48 [1.09-2.01]; p
- Published
- 2016
7. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast
- Author
-
Burcak Yilmaz, Mustafa Benekli, Ahmet Bilici, Faysal Dane, Banu Ozturk, Nuriye Ozdemir, Mehmet Emin Kalender, Emin Tamer Elkiran, Mahmut Gumus, Mesut Seker, Basak Oven Ustaalioglu, Ali Ünal, and ŞEKER, MESUT
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Pathology ,Systemic disease ,medicine.medical_treatment ,Breast Neoplasms ,Kaplan-Meier Estimate ,Antibodies, Monoclonal, Murine-Derived ,Primary Breast Lymphoma ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,skin and connective tissue diseases ,Cyclophosphamide ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,L-Lactate Dehydrogenase ,business.industry ,Obstetrics and Gynecology ,General Medicine ,Middle Aged ,medicine.disease ,Lymphoma ,Radiation therapy ,Treatment Outcome ,Doxorubicin ,Vincristine ,Prednisone ,Female ,Lymphoma, Large B-Cell, Diffuse ,Rituximab ,business ,Diffuse large B-cell lymphoma - Abstract
Non-Hodgkin lymphomas of the breast are uncommon cancers that occur as either primary extranodal diseases or secondary localizations of a systemic disease. The term "primary breast lymphoma" (PBL) is used to define malignant lymphomas primarily occurring in the breast in the absence of previously detected lymphoma localizations. In this report, we analyzed nine patients with primary diffuse large B cell lymphoma (DLBCL) of breast.Patients with newly diagnosed PBLs treated between 1997 and 2009 in five institutions were retrospectively evaluated.The median age of the patients with PBL was 49 years (range 30-82 years), and four patients had left-sided and five had right-sided disease. All of the nine patients were classified as DLBCL. Five patients with DLBCL received chemotherapy followed by involved-field or elective-field radiotherapy and four received chemotherapy alone. Complete remission (CR) following primary treatment for all patients with PBL except for two cases was obtained. In two patients, recurrence occurred. At the median follow-up of 24.2 months, the 5-year OS rate was 76.2%. Univariate analysis indicated that age, ECOG PS, clinical stage, international prognostic index score, lactate dehydrogenase levels and the presence of B symptoms were not important prognostic factors in our study.Our series contained a small sample size, but it is interesting because it included only DLBCL cases. However, definitive conclusions about treatment and follow-up options of patients cannot be made in such a small series of patients. There are very few reports of patients with PBL treated with R-CHOP rather than CHOP alone. The followup is probably still too short and sample size very few to know how R-CHOP compares with CHOP-treated patients in other series, but this is definitely worth looking at in more detail when reasonable median follow-up has been achieved and sample size are sufficient.
- Published
- 2010
8. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)
- Author
-
Emel Sezer, Mahmut Gumus, Hatice Odabas, Serkan Menekse, Banu Ozturk, Erkan Arpaci, Ali Inal, Abdurrahman Isikdogan, Kübra Aydın, Zuhat Urakci, Mehmet Metin Seker, Ilhan Hacibekiroglu, Turkan Ozturk Topcu, Emin Tamer Elkiran, Dogan Uncu, Sener Cihan, Mevlide İnanc, Suna Cokmert, Caglayan Geredeli, Yusuf Gunaydin, Hilmi Kodaz, Bala Basak Oven Ustaalioglu, Ali Suner, Mukremin Uysal, Oznur Bal, Didem Tastekin, Ozgur Tanriverdi, Ayse Ocak Duran, Mehmet Bilici, Tokat Gaziosmanpaşa Üniversitesi, MÜ, [Inal, Ali] Mersin Hosp, Dept Med Oncol, Mersin, Turkey -- [Sezer, Emel] Mersin Univ, Dept Med Oncol, Mersin, Turkey -- [Kodaz, Hilmi -- Hacibekiroglu, Ilhan] Trakya Univ, Dept Med Oncol, Edirne, Turkey -- [Odabas, Hatice -- Aydin, Kubra] Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Tastekin, Didem] Istanbul Univ, Dept Med Oncol, Istanbul, Turkey -- [Cihan, Sener] Istanbul Univ, Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Gumus, Mahmut] Bezmialem Vakif Univ, Dept Med Oncol, Istanbul, Turkey -- [Ustaalioglu, Bala Basak Oven] Haydarpasa Numune Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Cokmert, Suna] Kent Hosp, Dept Med Oncol, Istanbul, Turkey -- [Duran, Ayse Ocak] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey -- [Inanc, Mevlide] Kayseri Numune Educ & Res Hosp, Dept Med Oncol, Kayseri, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Dept Med Oncol, Sivas, Turkey -- [Elkiran, Emin Tamer] Inonu Univ, Dept Med Oncol, Malatya, Turkey -- [Gunaydin, Yusuf] Gazi Univ, Dept Med Oncol, Ankara, Turkey -- [Uncu, Dogan] Ankara Numune Training & Res Hosp, Dept Med Oncol, Manisa, Turkey -- [Bal, Oznur] Ankara Onkol Educ & Res Hosp, Dept Med Oncol, Manisa, Turkey -- [Menekse, Serkan] Celal Bayar Univ, Dept Med Oncol, Manisa, Turkey -- [Topcu, Turkan Ozturk] Karadeniz Tech Univ, Dept Med Oncol, Trabzon, Turkey -- [Urakci, Zuhat -- Isikdogan, Abdurrahman] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey -- [Bilici, Mehmet] Ataturk Univ, Dept Med Oncol, Erzurum, Turkey -- [Geredeli, Caglayan] Konya Numune Hosp, Dept Med Oncol, Konya, Turkey -- [Arpaci, Erkan] Sakarya Univ, Dept Med Oncol, Sakarya, Turkey -- [Ozturk, Banu] Gaziosmanpasa Univ, Dept Med Oncol, Yozgat, Turkey -- [Uysal, Mukremin] Afyon Kocatepe Univ, Dept Med Oncol, Afyon, Turkey -- [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Dept Med Oncol, Mugla, Turkey -- [Suner, Ali] Gaziantep Univ, Dept Med Oncol, Gaziantep, Turkey, Tanriverdi, Ozgur -- 0000-0002-0598-7284, Department of Medical Oncology, Mersin Hospital, Mersin, Turkey, Department of Medical Oncology, Trakya University, Edirne, Turkey, Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey, Department of Medical Oncology, Erciyes University, Kayseri, Turkey, Department of Medical Oncology, Cumhuriyet University, Sivas, Turkey, Department of Medical Oncology, Kayseri Numune Education and Research Hospital, Kayseri, Turkey, Department of Medical Oncology, Inonu University, Malatya, Turkey, Department of Medical Oncology, Gazi University, Ankara, Turkey, Department of Medical Oncology, Celal Bayar University, Manisa, Turkey, Department of Medical Oncology, Karadeniz Teknik University, Trabzon, Turkey, Department of Medical Oncology, Dicle University, Diyarbakir, Turkey, Department of Medical Oncology, Istanbul University, Istanbul, Turkey, Department of Medical Oncology, Atatürk University, Erzurum, Turkey, Department of Medical Oncology, Okmeydani Education and Research Hospital, Istanbul University, Istanbul, Turkey, Department of Medical Oncology, Konya Numune Hospital, Konya, Turkey, Department of Medical Oncology, Mersin University, Mersin, Turkey, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Turkey, Department of Medical Oncology, Sakarya University, Sakarya, Turkey, Department of Medical Oncology, Gaziosmanpasa University, Yozgat, Turkey, Department of Medical Oncology, Ankara Onkoloji Education and Research Hospital, Turkey, Department of Medical Oncology, Afyon Kocatepe University, Afyon, Turkey, Department of Medical Oncology, Mugla Sitki Kocman University, Mugla, Turkey, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey, Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey, Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey, and Department of Medical Oncology, Kent Hospital, Istanbul, Turkey
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Prognostic variable ,medicine.medical_specialty ,Multivariate analysis ,medicine.medical_treatment ,Medical Oncology ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Cranial Irradiation ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Lung cancer ,non-small cell lung cancer ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,Chemotherapy ,Univariate analysis ,Brain Neoplasms ,business.industry ,Proportional hazards model ,A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)-, JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, ss.578-582, 2018 [Inal A., Kodaz H., Odabas H., Duran A. O. , Seker M. M. , Inanc M., ELKIRAN E. T. , Gunaydin Y., Menekse S., Topcu T. O. , et al., -Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases] ,prognostic factors ,Brain metastases ,General Medicine ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,medicine.disease ,respiratory tract diseases ,Treatment Outcome ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Non small cell ,business - Abstract
WOS: 000435353000019, PubMed ID: 29893321, Purpose: Almost half of all patients diagnosed with non-small cell lung cancer (NSCLC) have distant metastases at presentation. One-third of patients with NSCLC will have brain metastases. Without effective treatment, the median survival is only 1 month. However, it is difficult to treat brain metastases with systemic chemotherapy since the agents have difficulty crossing the blood-brain barrier. Therefore, it is important to estimate the patient's survival prognosis. The aim of this study was to analyze prognostic factors for survival in Turkish patients who received chemotherapy after cranial irradiation for NSCLC with brain metastases. Methods: We retrospectively reviewed 698 patients with brain metastases resulting from NSCLC. Ten potential prognostic variables were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors associated with overall survival (OS). Results: Among the 10 variables for univariate analysis, six were identified to have prognostic significance; these included sex, smoking history, histology, number of brain metastases, extracranial metastases, and neurosurgical resection. Multivariate analysis by the Cox proportional hazard model showed that a smoking history, extracranial metastases, and neurosurgical resection were independent negative prognostic factors for OS. Conclusion: Smoking history, extracranial metastases, and neurosurgical resection were considered independent negative prognostic factors for OS. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for more appropriate treatment options.
- Published
- 2018
9. Thymic epithelial neoplasia
- Author
-
Kadri Altundag, Ay§e Kars, Sercan Aksoy, Gülten Tekuzman, Yavuz Ozisik, Emin Tamer Elkiran, Mustafa Erman, Alev Turker, and Huseyin Abali
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Sepsis ,Internal medicine ,Biopsy ,medicine ,Humans ,Neoplasms, Glandular and Epithelial ,Stage (cooking) ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,Hematology ,medicine.diagnostic_test ,business.industry ,Thymus Neoplasms ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Pancytopenia ,Myasthenia gravis ,Surgery ,Survival Rate ,Oncology ,Female ,business ,Nephrotic syndrome ,Follow-Up Studies - Abstract
Primary thymic epithelial neoplasms (PTENs) are uncommon tumors of anterior mediastinum with a broad range of biological characteristics. We retrospectively reviewed 58 consecutive patients with a diagnosis of PTENs that were confirmed pathologically during 28 yr. There were 58 patients, 31 males (53.4%) and 27 females (46.6%), with a mean age of 43.6 +/-13.8 yr (range, 17-73 yr). Twenty-one (36.2%) patients presented at the Masaoka stage I, 13 (22.4%) patient at stage II, 18 (31.0%) patient at stage III, and 6 (10.4%) patients at stage IV. Forty-five (77.7%) patients had myasthenia gravis, 1 (1.7%) immune deficiency, 1 (1.7%) pancytopenia, and 1 (1.7%) nephrotic syndrome. No paraneoplastic syndrome was associated in 10 (17.2%) patients. Complete resection was accomplished in 41 (70.7%) patients, while incomplete resection was performed in 8 (13.8%) patients. In nine (15.5%) patients only biopsy was carried out. Radiotherapy was administered to 19 (32.8%) patients. Eleven (19.0%) out of 58 who presented at advanced stages (at least III) received chemotherapy. Median follow-up period was 59 mo (range, 1-278 mo). During the follow-up period, 17 deaths occurred. Five patients (29.4%) died of tumor-related causes, and the remaining 12 patients died of other causes (cardiovascular diseases [n = 1, 5.9%], sepsis [n = 4, 23.5%], and MG-related respiratory insufficiency [n = 7, 41.2%]). The overall survival rates at 5 yr and 10 yr were 63.9% and 54.2%, respectively. Tumor-related survival rates at 5 yr and 10 yr were 89.0% and 83.2%, respectively. In our series, disease stage, presence or absence of myasthenia gravis, and tumor size did not affect survival (p0.05), either. Complete resection of the tumor seems to be the best predictive factor for long-term survival.
- Published
- 2007
10. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
- Author
-
Metin Ozkan, Berna Oksuzoglu, Akif Akbulat, Alper Sevinc, Banu Bayar, Hasan Şenol Coşkun, Emin Tamer Elkiran, Devrim Cabuk, Suayib Yalcin, Mustafa Benekli, Ahmet Ozet, and Temel Onkoloji
- Subjects
Oncology ,Sorafenib ,medicine.medical_specialty ,Pathology ,Turkish population ,endocrine system diseases ,overall survival ,Multiplex-PCR ,OncoTargets and Therapy ,advanced thyroid cancer ,Refractory ,Internal medicine ,medicine ,otorhinolaryngologic diseases ,Pharmacology (medical) ,Thyroid cancer ,Chronic otitis media with effusion ,Tumor marker ,Original Research ,business.industry ,Thyroid ,Medullary thyroid cancer ,medicine.disease ,Haemophilus influenzae ,digestive system diseases ,Confidence interval ,Onkoloji ,medicine.anatomical_structure ,Streptococcus pneumoniae ,sorafenib ,business ,Moraxella catarrhalis ,medicine.drug - Abstract
Mustafa Benekli,1 Suayib Yalcin,2 Metin Ozkan,3 Emin Tamer Elkiran,4 Alper Sevinc,5 Devrim Cabuk,6 Hasan Senol Coskun,7 Berna Oksuzoglu,8 Banu Bayar,9 Akif Akbulat,9 Ahmet Ozet1 On behalf of Turkish Thyroid Cancer Study Group 1Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, 2Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, 3Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, 4Department of Medical Oncology, Inonu University Faculty of Medicine, Malatya, 5Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, 6Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, 7Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, 8Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, 9Ministry of Health of Turkey, General Directorate of Pharmaceuticals and Medical Devices, Ankara, Turkey Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication. Patients and methods: Patients with advanced DTC and MTC were retrospectively identified from the Turkish Ministry of Health database. Data on these patients were prospectively collected before permission is granted to use sorafenib. Results: Thirty patients with complete data were analyzed: 14 DTC (papillary number [n] =10; follicular n=4) and 16 MTC. The median age of the patients was 57 years (range: 28–79 years), and there were 18 males and 12 females. All DTC patients were iodine refractory and had received a median three doses of radioactive iodine (range: 1–7 doses). Sorafenib was used for a median of 12 months (range: 1–49 months). The overall response rate was 20%, all partial responses, with no complete response. The overall response rate was 14% in DTC and 25% in MTC patients. The median progression-free survival (PFS) was 17.1 months (95% confidence interval [CI]: 7.3–26.8) and overall survival (OS) was not reached. The 2-year PFS and OS were 39% and 68%, respectively. DTC and MTC patients had similar survival outcomes: median PFS of 21.3 months (95% CI: 5.8–36.7) versus 14.5 months (95% CI: 3.7–25.2), respectively (P=0.36), with the median OS not reached in either group (P=0.17). Tumor marker levels did not have any prognostic or predictive role. The toxicity profile was similar to that of other sorafenib trials. Conclusion: Sorafenib is an effective and well-tolerated treatment in advanced thyroid cancers. Keywords: advanced thyroid cancer, sorafenib, overall survival
- Published
- 2014
11. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology
- Author
-
Oznur Bal, Arife Ulas, Necati Alkis, Mevlude Inanc, Ahmet Bilici, Alper Sevinc, Lokman Koral, Gulnihal Tufan, Tugba Yavuzsen, Nalan Akgul Babacan, Metin Ozkan, Mesut Seker, Ali Inal, Emin Tamer Elkiran, Tulay Akman, Bala Basak Oven Ustaalioglu, Mahmut Gumus, ŞEKER, MESUT, and Selçuk Üniversitesi
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Carcinoid tumors ,Sex Cord-Gonadal Stromal Tumors ,Ovary ,Internal medicine ,medicine ,Humans ,Progression-free survival ,Stage (cooking) ,Rare Ovarian Tumors ,Survival rate ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Ovarian Neoplasms ,Univariate analysis ,business.industry ,Overall Survival ,Prognostic Factors ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Middle Aged ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Prognosis ,Progression-Free Survival ,Survival Rate ,medicine.anatomical_structure ,Female ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
WOS: 000329829200052, PubMed: 24377556, Background: Non-epithelial malignant ovarian tumors and clear cell carcinomas, Brenner tumors, transitional cell tumors, and carcinoid tumors of the ovary are rare ovarian tumors (ROTs). In this study, our aim was to determine the clinicopathological features of ROT patients and prognostic factors associated with survival. Materials and Methods: A total of 167 patients with ROT who underwent initial surgery were retrospectively analyzed. Prognostic factors that may influence the survival of patients were evaluated by univariate and multivariate analyses. Results: Of 167 patients, 75 (44.9%) were diagnosed with germ-cell tumors (GCT) and 68 (40.7%) with sex cord-stromal tumors (SCST); the remaining 24 had other rare ovarian histologies. Significant differences were found between ROT groups with respect to age at diagnosis, tumor localization, initial surgery type, tumor size, tumor grade, and FIGO stage. Three-year progression-free survival (PFS) rates and median PFS intervals for patients with other ROT were worse than those of patients with GCT and SCST (41.8% vs 79.6% vs 77.1% and 30.2 vs 72 vs 150 months, respectively; p=0.01). Moreover, the 3-year overall survival (OS) rates and median OS times for patients with both GCT and SCST were better as compared to patients with other ROT, but these differences were not statistically significant (87.7% vs 88.8% vs 73.9% and 170 vs 122 vs 91 months, respectively; p=0.20). In the univariate analysis, tumor localization (p
- Published
- 2014
12. Childhood, adolescents, and young adults (≤25 y) colorectal cancer: study of Anatolian Society of Medical Oncology
- Author
-
Dogan Koca, Kaan Helvaci, Mahmut Gumus, Muhammet Ali Kaplan, Abdurrahman Isikdogan, Faysal Dane, Ali Inal, Mehmet Kucukoner, Ramazan Yildiz, Ulku Yalcintas Arslan, Caglayan Geredeli, Ali Suner, Tunc Guler, Nuriye Ozdemir, Mesut Seker, Emin Tamer Elkiran, Dogan Uncu, and ŞEKER, MESUT
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Abdominal pain ,Adolescent ,Colorectal cancer ,Disease ,Metastasis ,Young Adult ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Young adult ,Family history ,Stage (cooking) ,Child ,Neoplasm Staging ,business.industry ,Retrospective cohort study ,Hematology ,medicine.disease ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Female ,medicine.symptom ,Colorectal Neoplasms ,business - Abstract
PURPOSE To evaluate the clinicopathologic characteristics and treatment outcomes of young patients with colorectal cancer (CRC). METHODS Between May 2003 and June 2010, 76 patients were found eligible for this retrospective study. Age, sex, presenting symptoms, patients with acute presentation, family history, presence of polyps, histologic features, localization and stage of the tumor, treatment outcomes, time and site of recurrence, sites of metastasis, and survival outcomes were recorded from the patient files. RESULTS Seventy-six patients (55.3% male) with a median age of 23 years were evaluated. Patients were evaluated in 2 groups as follows: child-adolescent (0 to 19 y, n=20) and young adult (20 to 25 y, n=56). Sex and symptoms (abdominal pain and rectal bleeding) were significantly differed between the groups and acute presentation was close to statistical significance. Overall survival significantly increased in patients undergoing curative surgery (P
- Published
- 2013
13. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer
- Author
-
Mustafa Benekli, Abdurrahman Isikdogan, Meltem Baykara, Metin Ozkan, Mevlude Inanc, Suleyman Buyukberber, Veli Berk, Alper Sevinc, Muhammet Ali Kaplan, Ugur Coskun, Halit Karaca, Umut Demirci, and Emin Tamer Elkiran
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Epidemiology ,medicine.medical_treatment ,Neutropenia ,Adenocarcinoma ,Risk Factors ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Lung cancer ,Aged ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,business.industry ,Public Health, Environmental and Occupational Health ,Adenocarcinoma, Bronchiolo-Alveolar ,Middle Aged ,medicine.disease ,Prognosis ,Chemotherapy regimen ,Gemcitabine ,Survival Rate ,Regimen ,Carcinoma, Squamous Cell ,Carcinoma, Large Cell ,Female ,Neoplasm Recurrence, Local ,business ,Febrile neutropenia ,Progressive disease ,medicine.drug ,Follow-Up Studies - Abstract
Purpose: The aim of this retrospective study was to determine response rates, progression-free survival (PFS), overall survival (OS) and toxicity of gemcitabine and paclitaxel combinations with advanced or metastatic non-small cell lung cancer patients (NSCLC) who have progressive disease after platinum-based first-line chemotherapy. Methods: We retrospectively evaluated the file records of patients treated with gemcitabine plus paclitaxel in advanced or metastatic NSCLC cases in a second-line setting. The chemotherapy schedule was as follows: gemcitabine 1500 mg/m(2) and paclitaxel 150 mg/m(2) administered every two weeks. Results: Forty-eight patients (45 male, 3 female) were evaluated; stage IIIB/IV 6/42; PS0, 8.3%, PS1, 72.9%, PS2, 18.8%; median age, 56 years old (range 38-76). Six (12.5%) patients showed a partial response (PR), 13 (27.1%) stable disease (SD), and 27 (56.3%) progressive disease (PD). The median OS was 6.63 months (95% CI 4.0-9.2); the median PFS was 2.7 months (95% CI 1.8-3.6). Grade 3 and 4 hematologic toxicities, including neutropenia (n=4, 8.4%), and anemia (n=3, 6.3%) were encountered, but no grade 3 or 4 thrombocytopenia. One patient developed febrile neutropenia. There were no interruption for reasons of toxicity and no exitus related to therapy. Conclusion: The combination of two-weekly gemcitabine plus paclitaxel was an effective and well-tolerated second-line chemotherapy regimen for advanced or metastatic NSCLC patients previously treated with platinum-containing chemotherapy. Although the most common and dose limiting toxicities were neutropenia and neuropathy, this regimen was tolerated well by the patients.
- Published
- 2012
14. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology
- Author
-
Berna Oksuzoglu, Ramazan Yildiz, Zuhat Urakci, Ulku Yalcintas Arslan, Dogan Koca, Mevlude Inanc, Ugur Coskun, Ayse Durnali, Emin Tamer Elkiran, Nuriye Ozdemir, Adem Dayan, Lutfiye Demir, Mehmet Kucukoner, Murat Koçer, Muhammet Ali Kaplan, Ali Inal, Mustafa Oktay Tarhan, C. Geredeli, Suleyman Alici, Abdurrahman Isikdogan, Cem Boruban, Ali Suner, Ozge Gumusay, Tulay Akman, and Nur Sener
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Combination therapy ,Receptor, ErbB-2 ,Breast Neoplasms ,Lapatinib ,Antibodies, Monoclonal, Humanized ,Deoxycytidine ,Capecitabine ,Breast cancer ,Surgical oncology ,Trastuzumab ,Internal medicine ,mental disorders ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Pharmacology (medical) ,Radiology, Nuclear Medicine and imaging ,skin and connective tissue diseases ,Aged ,Retrospective Studies ,business.industry ,Brain Neoplasms ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,Clinical trial ,Treatment Outcome ,Quinazolines ,Female ,Fluorouracil ,business ,medicine.drug ,Brain metastasis - Abstract
In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis.Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis. Patients who only received trastuzumab-based therapy after the development of brain metastases were accepted as the historic control group for survival analyses (n = 65). Patients who received both drugs consecutively or sequentially were excluded from the analyses (n = 34).Median age among 46 patients who received lapatinib plus capecitabine therapy was 45 years (27-76), and median time for development of brain metastases was 11.9 months (0-69 months). Twenty-six out of 38 patients who received lapatinib plus capecitabine and had extracranial metastasis showed partial response or stable diseases (68.4 %). Grade 3-4 toxicity was observed in eight patients (17.3 %). Median overall survival (OS) in patients treated with lapatinib plus capecitabine was significantly increased compared to that in patients treated with trastuzumab-based therapy (19.1 vs. 12 months, respectively, p = 0.039). The incidence of cerebral death was slightly decreased in patients who received lapatinib plus capecitabine compared to those who received trastuzumab-based therapy (32 vs. 43.4 %, p = 0.332). In the multivariate analysis, lapatinib plus capecitabine therapy remained an independent positive predictor for survival [odds ratio (OR), 0.57; p = 0.02].Although this retrospective multicenter study had several limitations, the results suggest that undergoing lapatinib plus capecitabine therapy after the diagnosis of brain metastasis may further improve survival compared to undergoing only trastuzumab-based therapy.
- Published
- 2012
15. Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: A retrospective analysis of multicenter study
- Author
-
Nuriye Ozdemir, Tugba Kos, Mustafa Dikilitas, Suleyman Buyukberber, Metin Ozkan, Emin Tamer Elkiran, Ozan Balakan, A. Gok Durnali, Faysal Dane, Gamze Goksel, C. Geredeli, Ali Inal, Dogan Uncu, Efnan Algin, Ramazan Yildiz, Mahmut Gumus, Kaan Helvaci, Muhammet Ali Kaplan, Hakan Harputluoglu, and Abdurrahman Isikdogan
- Subjects
Oncology ,Cisplatin ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Locally advanced ,Metastatic Pancreatic Adenocarcinoma ,medicine.disease ,humanities ,Gemcitabine ,body regions ,Multicenter study ,Pancreatic cancer ,Internal medicine ,Advanced disease ,medicine ,Retrospective analysis ,business ,medicine.drug - Abstract
e14534 Background: The majority of patients with pancreatic cancer is advanced disease The aim of this retrospective multicenter study is to evaluated the efficiency of gemcitabine alone versus gem...
- Published
- 2011
16. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population
- Author
-
Emin Tamer Elkiran, Bilge Aygen, Süleyman Serdar Koca, Aziz Karaoglu, Nefsal Mar, and Ferit Gürsu
- Subjects
Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Turkey ,lcsh:RC254-282 ,Antioxidants ,Arylesterase ,chemistry.chemical_compound ,High-density lipoprotein ,Internal medicine ,Genetics ,Biomarkers, Tumor ,Medicine ,Humans ,Aged ,biology ,Triglyceride ,business.industry ,Aryldialkylphosphatase ,Paraoxonase ,Case-control study ,Middle Aged ,Free radical scavenger ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,PON1 ,Enzyme Activation ,Endocrinology ,Oncology ,chemistry ,Case-Control Studies ,Immunology ,biology.protein ,business ,Carboxylic Ester Hydrolases ,Research Article - Abstract
Background Lung cancer (LC) is the leading cause of cancer-related deaths. Oxidative DNA damage may contribute to the cancer risk. The antioxidant paraoxonase (PON1) is an endogenous free radical scavenger in the human body. The aim of this study was to determine serum PON1 and arylesterase (ARE) activities in patients with newly diagnosed LC. Methods This case control study involved a total of 39 patients with newly diagnosed LC (untreated) and same number of age- and sex-matched healthy individuals. Serum PON1 and ARE activities in addition to lipid parameters were measured in both groups. Results Serum PON1 and ARE activities were found to be lower in patients with LC compared to the controls (p = 0.001 and p = 0.018, respectively). The ratio of PON1/high density lipoprotein (HDL) was significantly lower in the LC group compared to the control one (p = 0.009). There were positive correlations between the serum levels of HDL and PON1 in both the control (r = 0.415, p = 0.009) and the LC groups (r = 0.496, p = 0.001), respectively. PON1 enzyme activity was calculated as three different phenotypes in both groups. In regard to lipid parameters, total cholesterol levels were significantly lower (p = 0.014) in the LC group whereas the other lipid parameters such as HDL, LDL, and triglyceride levels were not significantly different among groups. Conclusion Serum PON1 activity is significantly low in the LC group compared with the healthy controls. Metastasis status and cigarette smoking do not affect serum PON1 activity in the LC patients.
- Published
- 2007
17. 1619 Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA)
- Author
-
E. Cubukcu, Berna Oksuzoglu, Mehmet Aliustaoglu, Faysal Dane, A. Isýkdogan, Mustafa Benekli, Alper Sevinc, M. Ozkan, A. Karaoglu, Murat Koçer, Irfan Cicin, Emin Tamer Elkiran, and E. Ozaslan
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Turkish ,Low molecular weight heparin ,Cancer ,medicine.disease ,language.human_language ,Oncology ,Internal medicine ,medicine ,language ,Observational study ,business ,Venous thromboembolism - Published
- 2015
18. Metastatic osteosarcoma to the brain in adult patient
- Author
-
Emin Tamer Elkiran, Aziz Karaoglu, Bilge Aygen, and Kadri Altundag
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Neurology ,business.industry ,medicine.disease ,Internal medicine ,Metastatic osteosarcoma ,medicine ,Osteosarcoma ,Neurology (clinical) ,business - Published
- 2006
19. Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells
- Author
-
Yavuz Ozisik, Mustafa Cengiz, Ozden Altundag, Emin Tamer Elkiran, and Kadri Altundag
- Subjects
Oncology ,CA15-3 ,medicine.medical_specialty ,Antineoplastic Agents ,Breast Neoplasms ,Metastasis ,Breast cancer ,Cancer stem cell ,Internal medicine ,medicine ,Humans ,skin and connective tissue diseases ,business.industry ,Hematopoietic stem cell ,Cancer ,Granulocyte-Macrophage Colony-Stimulating Factor ,General Medicine ,medicine.disease ,Survival Rate ,medicine.anatomical_structure ,Chemotherapy, Adjuvant ,Cancer cell ,Neoplastic Stem Cells ,Stem cell ,Neoplasm Recurrence, Local ,business - Abstract
All cancers are clonal and represent the progeny of a single cell. The unclear point is which clonogenic cells within the tumor clone possess tumor-initiating cell (T-IC) function and are capable of maintaining tumor growth. Stem cells have the ability to divide almost indefinitely. The division can give rise to a new stem cell as well as differentiated cells of the tumor. Breast tumors are comprised of phenotypically diverse populations of breast cancer cells. Among them, the breast cancer stem cell is important for regrowth of tumor and metastasis. Granulocyte-colony stimulating factor (G-CSF) stimulates the pluripotent stem cell beside neutrophil precursors. Breast cancer stem cells which have not been characterized totally may carry the almost identical antigens with hematopoietic stem cell. The dose-intense therapies with the addition of G-CSF in the adjuvant treatment of breast cancer improved clinical outcomes significantly. Presence of micrometastasis in bone marrow of the breast cancer patients is predictor of relapse free survival and important prognostic factor. Actually, breast cancer stem cells in the thousands of micrometastatic cancer cells have the capacity to repopulate and metastasise. We hypothesize that G-CSF use in adjuvant treatment of breast cancer may activate and repopulate these dormant breast cancer stem cells besides its stimulation on blood stem cells. So activated breast cancer stem cells become chemosensitive to cell-cycle specific various chemotherapeutic agents. Improvement in overall survival in operable breast cancer patients having been treated by dose-dense therapies may also be explained by this mechanism.
- Published
- 2003
20. Frequency and risk factors of potential drug interactions in breast cancer patients
- Author
-
İbrahim Hakkı Dursun, Emin Tamer Elkiran, Hakan Harputluoglu, Fatma Acar, Mehmet Salih Kilic, and Ali Yigit
- Subjects
Oncology ,Drug ,Gynecology ,Cancer Research ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Cancer ,medicine.disease ,Breast cancer ,Internal medicine ,medicine ,skin and connective tissue diseases ,business ,media_common - Abstract
e17669 Background: Breast cancer is the most common cancer in women. Breast cancer is seen in one of every six women during their lifetime period. In addition to cytotoxic treatment, these patients...
- Published
- 2014
21. The effect of front-line chemotherapy on overall survival in patients with malignant pleural mesothelioma
- Author
-
Hakan Harputluoglu, Emin Tamer Elkiran, and Alper Sevinc
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,Pleural mesothelioma ,medicine.medical_treatment ,High mortality ,Front line ,Surgery ,Internal medicine ,Overall survival ,Etiology ,Medicine ,In patient ,Risk factor ,business - Abstract
e18560 Background: Malignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. Methods: The present study retrospectively evaluated the 141 patients from the database. Results: There were 80 males and 61 females with a mean age of 56 ± 1.07 years. The median survival in patients who were administered front-line chemotherapy was 17 months (95% CI: 13.19-20.81). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. For the patients who received pemetrexed-platinum regimen, a median of 6 cycles of chemotherapy was administered and 50 patients (47.2%) were able to receive all 6 cycles as planned. For the patients who received gemcitabine-platinum regimen, a median of 6 cycles of chemotherapy was administered and 19 patients (54.3%) were able to receive all 6 cycles. Median survival was found 16 months in the pemetrexed-platinum regimen and 26 months in the gemcitabine- platinum regimen. There was no statistically significant difference between the patients who received pemetrexed-platinum and gemcitabine-platinum regimens in terms of the median overall survival (p = 0.15). Conclusions: Results of our study suggest that chemotherapy prolongs overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found to be similar.
- Published
- 2013
22. Lapatinib or trastuzumab? Which anti-HER2 treatment is more effective in the treatment of patients with HER2-positive breast cancer with brain metastases? An Anatolian Society of Medical Oncology Study
- Author
-
Dogan Koca, Ulku Yalcintas Arslan, Ayse Durnali, Murat Koçer, Abdurrahman Isikdogan, Ramazan Yildiz, Mevlude Inanc, Lutfiye Demir, Ugur Coskun, Ilhan Oztop, Nuriye Ozdemir, Ali Inal, Muhammet Ali Kaplan, Mehmet Kucukoner, C. Geredeli, Nur Sener, Emin Tamer Elkiran, Ozge Gumusay, Suleyman Alici, and Ali Suner
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Lapatinib ,medicine.disease ,Metastatic breast cancer ,Confidence interval ,Radiosurgery ,Breast cancer ,Trastuzumab ,HER2 Positive Breast Cancer ,Internal medicine ,medicine ,Anti her2 ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
638 Background: In the present study, we investigate that which treatment choice is more effective in the human epidermal growth factor receptor 2 (HER2) positive breast cancer patients with brain metastases. Methods: Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 111 patients treated with lapatinib or trastuzumab after brain metastases eligible for the analyses were identified. Patients received both drugs consecutively or sequentially were excluded from the study. Results: Median age was 44 years (27-76) and 46 of the 111 patients (41.5%) had received lapatinib. Median time to development of brain metastases was 12.2 months (0-71). Sixteen patients (14.4%) had undergone surgery, 33 (29.7%) radiosurgery, and 108 (97.2%) whole brain radiation therapy (WBRT). Median overall survival (OS) after brain metastases was 15 months(95% confidence interval (CI): 12.3-17.6). Lapatinib usage was prolonged OS over trastuzumab alone (19.1 months vs 12 months, p=0.039).Other parameters affecting the survival were Karnofsky performance score (KPS, >70), number of brain metastases (>3), extracranial metastases (≥2), performed neurosurgery, and received radiosurgery. After correction for potential confounders, lapatinib therapy remained an independent positive predictor for survival [Odds ratio (OR), 0.57; p=0.02). Conclusions: Although this retrospective multi-center study had several limitations, study results suggest that the usage of lapatinib after brain metastases prolonged survival compared to the usage of trastuzumab. This result should be support with prospective studies.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.